SLU-PP-332
Also known as: Exercise Mimetic, ERR Agonist
Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator
Overview
Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.
Key benefits
- Exercise mimetic effects without physical activity
- 12% weight loss in 28 days
- 70% increased endurance
- 25% enhanced fatty acid oxidation
- Improved insulin sensitivity
- Reduced hepatic steatosis
- Cardiac protection
- Reversal of age-related mitochondrial dysfunction
Mechanism of action
Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.
Molecular data
- Type
- Synthetic ERR agonist
- Half-life
- Under investigation (no human PK data)
Sequence
(E)-4-Hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide
Indications
What the research community uses this compound for, with self-reported effectiveness.
Metabolic Health
Weight Loss & Body Composition
Most effective12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.
Insulin Sensitivity & Glucose Control
Most effectiveSignificantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.
Energy Expenditure Enhancement
Most effectiveIncreases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.
Liver Health & NAFLD
Most effectiveReduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.
Exercise Performance
Endurance Improvements
Effective70% increase in running time and 45% increase in running distance in preclinical models.
Muscle Fiber Remodeling
EffectiveIncreased type IIa oxidative skeletal muscle fibers with enhanced oxidative capacity.
Cardiovascular
Cardiac Function Improvement
ModerateImproved ejection fraction in heart failure models with reduced cardiac fibrosis.
Anti-Aging
Mitochondrial Aging Reversal
ModerateFirst compound to reverse age-related mitochondrial dysfunction in 21-month-old mice.
Kidney Protection
Age-Related Kidney Disease
ModerateReversed age-related albuminuria increase and prevented podocyte loss in elderly mice.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Research compound - IP injection in animals only. No human administration protocols established.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Standard Metabolic Protocol | 50 mg/kg (animal dosing) | Twice daily | Intraperitoneal injection (IP) |
| Acute Exercise Enhancement | 50 mg/kg (animal dosing) | Single dose 1 hour pre-exercise | Intraperitoneal injection (IP) |
| Extended Treatment | 50 mg/kg (animal dosing) | Twice daily for 4-8 weeks | Intraperitoneal injection (IP) |
Preparation
You will need
- Bacteriostatic water (BAC) required
- Sterile technique essential
Steps
- WARNING: Not tested in humans - research only
- Do NOT use outside approved research protocols
- Dosing cannot be extrapolated from animals to humans
- No human clinical trials initiated as of 2025
- Oral formulation in development
- Consult medical professionals before experimental use
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Metformin
MonitorBoth affect mitochondrial function and AMPK pathways - may have additive metabolic effects. Monitor blood glucose closely.
Insulin
MonitorEnhanced insulin sensitivity may require significant dose reduction to prevent hypoglycemia.
Tirzepatide
MonitorDifferent mechanisms affecting weight loss and metabolism - combination could have additive effects.
Semaglutide
MonitorCombining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely.
5-Amino-1MQ
CompatibleDistinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.
NAD+
SynergisticComplementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.
CJC-1295
CompatibleGH optimization may complement metabolic enhancement for body composition without known interactions.
Ipamorelin
CompatibleMay preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Hours 1-6
Metabolic shift toward fat oxidation within 2 hours; gene expression changes at 3-6 hours; enhanced exercise performance 1 hour post-dose
- Week 1
Increased resting energy expenditure measurable; enhanced fatty acid oxidation by 25%; improved grip strength by day 6
- Week 2-4
Up to 12% weight loss by day 28; dramatic fat mass reduction; improved glucose tolerance; 45-70% endurance improvements; reduced hepatic steatosis
- Week 6-8
Cardiac improvements (ejection fraction, reduced fibrosis); age-related kidney dysfunction reversal; mitochondrial architecture restoration
- Long-term (5+ months)
Sustained anti-aging effects in aging studies; continued tissue mitochondrial improvement; duration after discontinuation unknown
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Animal studies show favorable safety with no severe effects at therapeutic doses
- Well-tolerated in rodents and canines
- No liver, kidney, or cardiac toxicity documented
- No lean mass loss
- Does not suppress hormones or act as stimulant
- Minor plasma cholesterol and liver enzyme changes in some studies
Stop signs — stop and seek advice
- Severe hypoglycemia (especially with diabetes medications)
- Any cardiovascular symptoms (chest pain, palpitations, shortness of breath)
- Signs of liver dysfunction (jaundice, dark urine, severe abdominal pain)
- Kidney problems (reduced urination, swelling, severe back pain)
- Severe headaches or neurological symptoms
- Allergic reactions (rash, hives, difficulty breathing, swelling)
Contraindications
- NOT FOR HUMAN USE - no approved human dose
- No human clinical trials conducted
- Potential interaction with diabetes medications
Monitoring
- Blood glucose if combined with insulin or metformin
- Weight loss rate if combined with other weight loss compounds
- Metabolic parameters in extended use
- Cardiac function if cardiac history present
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- Legitimate research supplier with Certificate of Analysis
- From reputable chemical suppliers (Cayman Chemical, Sigma-Aldrich)
- Proper labeling as 'Research Use Only'
- Batch numbers and purity data (typically >98%)
Warning signs
- Research chemical only - NOT FOR HUMAN USE
- NOT FDA approved - no human clinical trials
- Available only for legitimate research through licensed suppliers
Stop signs — don't use
- Any product marketed for human consumption is illegal
- Unknown purity or contamination without lab testing
- Lack of proper HPLC or mass spectrometry verification
- Products without 'Research Use Only' labeling
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
2025 · Molecular Metabolism
An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
SLU-PP-915, a chemically distinct orally bioavailable ERR pan-agonist, enhances aerobic exercise performance similarly to SLU-PP-332 when administered by injection, and maintains comparable efficacy when administered orally. Represents a major advance toward clinical translation.
2025 · GeroScience
Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study
Pilot study examining ERR agonism as a strategy to counteract age-related muscle atrophy associated with physical inactivity, supporting clinical relevance of the ERR pathway.
References
Primary literature and clinical-trial data informing this entry.
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP · Journal of Pharmacology and Experimental Therapeutics · 2024
Diet-induced obese mice, 50 mg/kg IP twice daily, 28 days: 12% body weight loss, 25% fatty acid oxidation increase, improved glucose tolerance, reduced hepatic steatosis. SLU-PP-332 mimics exercise-induced metabolic benefits.
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, Chatterjee A, Chrivia J et al. · ACS Chemical Biology · 2023
Multiple mouse models, 50 mg/kg IP: 70% increase in running time, 45% increase in running distance, increased type IIa oxidative muscle fibers. SLU-PP-332 is a synthetic ERR pan agonist with highest potency for ERRα.
Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney
Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, Jones BA, Bhasin K, Shults N, Qi Y, Krausz KW et al. · American Journal of Pathology · 2023
21-month-old mice, 8-week treatment with SLU-PP-332: Reversed age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines.
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, Rideb JRDC, Zhao Y, Hayes M, Yu K et al. · Circulation · 2024
Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival in pressure overload-induced heart failure without affecting cardiac hypertrophy. Transcriptionally activated fatty acid metabolism and mitochondrial function genes.
Last updated . How this page was sourced is described in the methodology.